A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 12
- Population
- ALL · 60 Years to 85 Years
- Duration
- 2026-04-01 to 2028-12-01
- Intervention
- Stemis™; Normal Saline
- Comparator
- Saline Placebo
- Outcomes measured
- Determination of the Maximum Feasible Dose (MFD) of Stemis™ based on the occurrence of Dose-Limiting Toxicities (DLTs)…; Incidence of Treatment-Emergent Adverse Events (TEAEs) — From first administration of study intervention through 26 wee…; Incidence of withdrawals due to adverse events (AEs) — From first administration of study intervention through 26 weeks…; Number of Participants with Clinically Significant Changes in Physical Examination Findings — From first administration…; Number of Participants with Clinically Significant Changes in Clinical Laboratory Test Results — From first administrat…; Number of Participants with Clinically Significant Changes in Vital Signs — From first administration of study interven…; Six-Minute Walk Test (6MWT) — From baseline through 26 weeks after the last dose; Hand Grip Strength - maximum force — From baseline through 26 weeks after the last dose; Short Physical Performance Battery (SPPB) - total score — From baseline through 26 weeks after the last dose; Clinical Frailty Scale (CFS) - score — From baseline through 26 weeks after the last dose; Falls Efficacy Scale-International (FES-I) - total score — From baseline through 26 weeks after the last dose; PROMIS Physical Function Short Form 20a - T-score — From baseline through 26 weeks after the last dose; World Health Organization Quality of Life-BREF (WHOQOL-BREF) - domain scores — From baseline through 26 weeks after the…; 12-Item Short Form Health Survey (SF-12) - Physical and Mental Component Summary scores — From baseline through 26 week…; Creatine Phosphokinase (CPK) — From baseline through 26 weeks after the last dose; N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) — From baseline through 26 weeks after the last dose
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Frailty · 100%Title contains controlled term: frailty. Abstract contains controlled term: frailty. Source terminology contains: frailty. Title supplies longevity context: frailty, frail. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.